Payment overview · 2025
General Payments
$2,276.06
95 reported records · 23 companies
Healthcare provider profile · identity verified
Aaron W Maddox, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SOUTHFIELD, MI · NPI 1235143777
Verified facts
What the public records show
CMS Open Payments records show Aaron W Maddox, M.D. received $2,276.06 in general payments during 2025 across 95 reported records.
Novo Nordisk Inc accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $510.56 | 22.4% | 22 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $386.10 | 17.0% | 20 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $252.85 | 11.1% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $160.11 | 7.0% | 10 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $129.17 | 5.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $124.74 | 5.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $84.71 | 3.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $81.80 | 3.6% | 4 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $77.21 | 3.4% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.03 | 3.2% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $72.30 | 3.2% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $45.02 | 2.0% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $41.72 | 1.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.64 | 1.7% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $36.06 | 1.6% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $24.76 | 1.1% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $23.67 | 1.0% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $22.89 | 1.0% | 1 | 2025 |
| Neuronetics, Inc. | Unresolved — no canonical attribution shown | $21.81 | 1.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $20.54 | 0.9% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.36 | 0.8% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.24 | 0.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $13.77 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,258.68 | 94 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $444.33 | 18 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $252.85 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $210.96 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $140.40 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $137.34 | 9 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $129.17 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $129.17 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $119.89 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $109.60 | 6 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $100.88 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $84.71 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $81.80 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $72.30 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.51 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.51 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $46.38 | 3 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $45.02 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $44.21 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $41.72 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $41.72 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $37.44 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $30.78 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $22.46 | 1 | 2025 |
Source payment records
|
|||||
| NEUROSTAR TMS THERAPY SYSTEM Normalized: neurostar tms therapy system |
Device | Neuronetics, Inc. | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 67 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 102 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
80 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
102 | 28 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 545 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 514 | 148 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 378 | 125 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 337 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 313 | 92 |
| Alprazolam | Alprazolam | 287 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 286 | 86 |
| Furosemide | Furosemide | 255 | 79 |
| Famotidine | Famotidine | 251 | 87 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 250 | 65 |
| Losartan Potassium | Losartan Potassium | 219 | 70 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 205 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 57 |
| Metformin Hcl | Metformin Hcl | 201 | 65 |
| Tramadol Hcl | Tramadol Hcl | 195 | 62 |
| Allopurinol | Allopurinol | 184 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 58 |
| Azithromycin | Azithromycin | 163 | 91 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 151 | 45 |
| Trazodone Hcl | Trazodone Hcl | 150 | 48 |
| Eliquis | Apixaban | 148 | 37 |
| Potassium Chloride | Potassium Chloride | 148 | 44 |
| Ibuprofen | Ibuprofen | 140 | 50 |
| Omeprazole | Omeprazole | 136 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 132 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 41 |
| Gabapentin | Gabapentin | 124 | 43 |
| Simvastatin | Simvastatin | 119 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 113 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 112 | 30 |
| Carvedilol | Carvedilol | 105 | 33 |
| Ozempic | Semaglutide | 102 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 102 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 101 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 101 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 21 |
| Sertraline Hcl | Sertraline Hcl | 85 | 28 |
| Naproxen | Naproxen | 84 | 25 |
| Montelukast Sodium | Montelukast Sodium | 81 | 24 |
| Linzess | Linaclotide | 80 | 22 |
| Nifedipine Er | Nifedipine | 80 | 21 |
| Ammonium Lactate | Ammonium Lactate | 79 | 28 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 77 | 23 |
| Atenolol | Atenolol | 67 | 18 |
| Farxiga | Dapagliflozin Propanediol | 67 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 18 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 65 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 64 | 17 |
| Lisinopril | Lisinopril | 64 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 63 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 32 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 60 | 22 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 57 | 18 |
| Diazepam | Diazepam | 56 | 13 |
| Hydrocortisone | Hydrocortisone | 56 | 20 |
| Januvia | Sitagliptin Phosphate | 56 | 13 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 55 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 54 | 25 |
| Valsartan | Valsartan | 53 | 16 |
| Jardiance | Empagliflozin | 52 | 15 |
| Ketoconazole | Ketoconazole | 52 | 11 |
| Trulicity | Dulaglutide | 52 | 11 |
| Amoxicillin | Amoxicillin | 51 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 13 |
| Pregabalin | Pregabalin | 50 | suppressed |
| Colchicine | Colchicine | 49 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 17 |
| Baclofen | Baclofen | 45 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 15 |
| Fluconazole | Fluconazole | 43 | 17 |
| Spironolactone | Spironolactone | 43 | 13 |
| Betamethasone Valerate | Betamethasone Valerate | 41 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | 13 |
| Metformin Hcl Er | Metformin Hcl | 40 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | 11 |
| Meclizine Hcl | Meclizine Hcl | 39 | 12 |
| Methocarbamol | Methocarbamol | 38 | 17 |
| Ondansetron Odt | Ondansetron | 38 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 31 |
| Glipizide | Glipizide | 37 | 11 |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 36 | 33 |
| Glipizide Er | Glipizide | 36 | suppressed |
| Meloxicam | Meloxicam | 36 | 14 |
| Valacyclovir | Valacyclovir Hcl | 35 | 14 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 34 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | 11 |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Prednisone | Prednisone | 31 | 14 |
| Temazepam | Temazepam | 30 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 30 | 11 |
| Azelastine Hcl | Azelastine Hcl | 29 | 11 |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 16 |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 26 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 26 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Indomethacin | Indomethacin | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 18 |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Clonidine | Clonidine | 23 | suppressed |
| Metolazone | Metolazone | 23 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 14 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Nystatin | Nystatin | 21 | 11 |
| Trulance | Plecanatide | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Terconazole | Terconazole | 18 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Epinephrine | Epinephrine | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Desoximetasone | Desoximetasone | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,276.06 · 95 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, AUSTEDO XR, Arikayce, BREZTRI, Brinsupri, CLOTTRIEVER BOLD CATHETER, Cologuard Collection Kit, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, DUPIXENT, EDARBI, FARXIGA, GEMTESA, GLASSIA, JARDIANCE, KRYSTEXXA, Kerendia, MOUNJARO, NEUROSTAR TMS THERAPY SYSTEM, NUCALA, OPSUMIT, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, TEZSPIRE, TRELEGY ELLIPTA, UBRELVY, UPTRAVI, Veozah, WAINUA, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error